|
TBC1D22B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.92370041907486E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.8706000082247E-09 |
| Normal-vs-Stage2 |
9.82939999999433E-05 |
| Normal-vs-Stage3 |
3.24109999949584E-07 |
| Normal-vs-Stage4 |
1.633610E-04 |
| Stage1-vs-Stage2 |
6.367000E-01 |
| Stage1-vs-Stage3 |
8.886400E-01 |
| Stage1-vs-Stage4 |
4.005600E-01 |
| Stage2-vs-Stage3 |
7.180800E-01 |
| Stage2-vs-Stage4 |
3.273000E-01 |
| Stage3-vs-Stage4 |
4.285000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.67730002004407E-09 |
| Normal-vs-AfricanAmerican |
1.993230E-04 |
| Normal-vs-Asian |
2.26339999999103E-05 |
| Caucasian-vs-AfricanAmerican |
2.101800E-01 |
| Caucasian-vs-Asian |
8.470600E-01 |
| AfricanAmerican-vs-Asian |
3.340200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.5968000000608E-07 |
| Normal-vs-Female |
6.49880038672279E-10 |
| Male-vs-Female |
7.389000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.10529976469354E-10 |
| Normal-vs-Age(41-60Yrs) |
7.86510001571372E-09 |
| Normal-vs-Age(61-80Yrs) |
1.620200E-04 |
| Normal-vs-Age(81-100Yrs) |
3.756300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.022400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.156200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.153000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.756550E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.635200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.101800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.907200E-01 |
| Classical-VS-Follicular |
8.991200E-01 |
| Classical-VS-Other |
6.076400E-01 |
| Classical-VS-Normal |
4.64119964682652E-10 |
| Tall-VS-Follicular |
9.319000E-01 |
| Tall-VS-Other |
5.865600E-01 |
| Tall-VS-Normal |
2.07669999999771E-05 |
| Follicular-VS-Other |
6.558400E-01 |
| Follicular-VS-Normal |
4.405300000343E-07 |
| Other-VS-Normal |
4.273600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.23969999990636E-07 |
| Normal-vs-N1 |
4.36799999999904E-05 |
| N0-vs-N1 |
4.778000E-01 |
|
|
